What non‑hormonal treatment options are available for a perimenopausal woman (approximately 45‑55 years old) with symptomatic uterine fibroids?

Non-Hormonal Treatment Options for Perimenopausal Women with Symptomatic Uterine Fibroids

For perimenopausal women with symptomatic fibroids, tranexamic acid is the first-line non-hormonal medical option, while NSAIDs can help with pain and bleeding; if medical management fails, uterine artery embolization (UAE) or MR-guided focused ultrasound (MRgFUS) are the preferred non-hormonal procedural interventions. 1

Medical Management (Non-Hormonal)

First-Line Pharmacologic Options

• Tranexamic acid: This is the primary non-hormonal medication that reduces bleeding symptoms in patients with fibroids 1

  • Works by inhibiting fibrinolysis
  • Does not affect fibroid size
  • Suitable for managing heavy menstrual bleeding without hormonal effects

• NSAIDs: Reduce both bleeding and pain symptoms 1

  • Anti-inflammatory mechanism helps with dysmenorrhea and bulk-related discomfort
  • Can be used alone or in combination with tranexamic acid

Important caveat: Medical management should be trialed before pursuing invasive therapies according to current guidelines 1. However, these medications only address symptoms and do not reduce fibroid volume, so they work best as a bridge to menopause when fibroids naturally regress.

Procedural Non-Hormonal Options

Uterine Artery Embolization (UAE)

UAE is usually appropriate as initial therapy for perimenopausal women with symptomatic fibroids 1. This is a well-established non-hormonal intervention with the following characteristics:

• Mechanism: Blocks blood supply to fibroids, causing them to shrink through ischemic necrosis
• Efficacy: Improves symptoms in 85-90% of patients 2
• Recovery: Outpatient or 1-day admission; faster return to activities than surgery
• Side effects: Pain, nausea, groin hematoma, fever (most resolve within 24-72 hours) 3
• Long-term outcomes: Quality of life improvement similar to hysterectomy, though hysterectomy is superior for controlling abnormal uterine bleeding 3

MR-Guided Focused Ultrasound (MRgFUS)

MRgFUS is a completely non-invasive non-hormonal option 1:

• Mechanism: Uses high-intensity ultrasound waves to thermally ablate fibroids under MRI guidance, causing coagulative necrosis without damaging surrounding tissue
• Procedure: Typically 1-day admission, no incisions
• Complications: Rare (skin burns, nerve damage, vaginal discharge, bowel injury, DVT, abdominal wall pain) 1
• Efficacy limitations: The FIRSTT trial showed MRgFUS had higher reintervention rates (30% vs 13%) and decreased symptom control compared to UAE 1
• Quality of life: Improvement was not significantly different from placebo in one RCT, and inferior to UAE at all time points 1

Critical comparison: While MRgFUS is the least invasive option, UAE demonstrates superior symptom control and lower reintervention rates 1. Choose MRgFUS for patients who prioritize complete non-invasiveness despite potentially needing retreatment.

Laparoscopic Radiofrequency Ablation

• Mechanism: Applies radiofrequency energy to shrink fibroids
• Recovery: 1-2 weeks
• Efficacy: Shows improvement in heavy menstrual bleeding and quality of life, though myomectomy showed greater improvement 3

Transcervical Radiofrequency Ablation

• Approach: Cervical route (no abdominal incisions)
• Recovery: 3-4 days
• Efficacy: Clinical trials showed significant improvement in quality of life, symptom severity, fibroid volume, and menstrual blood loss 3
• Side effects: Fibroid sloughing and cramping

Surgical Non-Hormonal Options (When Medical/Minimally Invasive Fails)

Hysteroscopic Myomectomy

• Indication: Specifically for pedunculated submucosal fibroids <5 cm 1
• Advantages: Shortest hospitalization, fastest return to activities
• Outcomes: Equivalent quality of life improvement to more invasive approaches at 2-3 months 1

Laparoscopic or Open Myomectomy

• Indication: Subserosal or intramural fibroids 1
• Advantages: Preserves uterus, improves quality of life up to 10 years 1
• Recovery: Laparoscopy offers shorter hospital stays than open approach 1

Hysterectomy

• Definitive treatment: Provides complete resolution of all fibroid-related symptoms 1
• Consideration: Most common treatment in the US (three-quarters of fibroid treatment) 1
• For perimenopausal women: Usually appropriate as next step if other treatments fail 1

Clinical Decision Algorithm

1. Start with non-hormonal medical management: Tranexamic acid ± NSAIDs 1

   • Trial for 3-6 months
   • Best for mild-moderate symptoms
   • Bridge to menopause if close (within 2-3 years)

2. If medical management fails or symptoms are severe:

   • UAE: First choice for most patients—best balance of efficacy, invasiveness, and reintervention rates 1, 2
   • MRgFUS: For patients who refuse any invasive procedure and accept higher reintervention risk 1
   • Radiofrequency ablation: Alternative minimally invasive option 3

3. If minimally invasive procedures fail or are contraindicated:

   • Myomectomy: If uterine preservation desired
   • Hysterectomy: Definitive solution if childbearing complete 1

Critical Pitfalls to Avoid

• Don't assume all fibroids will regress at menopause: While natural regression typically begins, some fibroids persist and remain symptomatic 4
• Rule out malignancy in perimenopausal/postmenopausal bleeding: Risk of uterine sarcoma increases with age (up to 10.1 per 1,000 in older patients) 1. Continued fibroid growth or bleeding after menopause should raise suspicion 1
• Don't overlook tranexamic acid: It's consistently recommended as the non-hormonal medical option but is often underutilized 1
• Set realistic expectations for MRgFUS: While appealing due to non-invasiveness, it has a 30% reintervention rate at 2 years 1